US Stock MarketDetailed Quotes
MNMD Mind Medicine
- 6.3100
- +0.2300+3.78%
Close Sep 19 16:00 ET
- 6.3001
- -0.0099-0.16%
Post 20:02 ET
513.83MMarket Cap-3093P/E (TTM)
6.4800High6.0900Low645.18KVolume6.2800Open6.0800Pre Close4.09MTurnover0.96%Turnover RatioLossP/E (Static)81.43MShares12.220052wk High2.54P/B425.71MFloat Cap2.410052wk Low--Dividend TTM67.47MShs Float86.5500Historical High--Div YieldTTM6.41%Amplitude2.1200Historical Low6.3390Avg Price1Lot Size
Mind Medicine Stock Forum
Sign in to post a comment
$Mind Medicine (MNMD.US)$ keep seeing crazy price targets for this company and the price keeps sinking? any insights? just a long term hold or another piece of trash?
3
$Mind Medicine (MNMD.US)$ junk company
1
1
$Mind Medicine (MNMD.US)$ Reuters· 4 mins ago
Mind Medicine (MindMed) Inc. Announces Proposed Public Offering
Mind Medicine (MindMed) Inc. Announces Proposed Public Offering
7
$Hoth Therapeutics (HOTH.US)$
$Mind Medicine (MNMD.US)$
$36 target!!!!!
https://www.moomoo.com/news/post/41181597/roth-mkm-initiates-mind-medicine-mnmdus-with-buy-rating-announces?futusource=news_stock_stockpagenews&ns_stock_id=37125992&report_id=37125992&report_type=stock&src=2&main_broker=WzEwMDdd&client_hour_clock=24&us_cid=73925127&channel=4&skintype=3&level=2&global_content={%22promote_content%22:%22mm:post:41181597%22,%22invite%22:73925127}&data_ticket=1721821266767476
$Mind Medicine (MNMD.US)$
$36 target!!!!!
https://www.moomoo.com/news/post/41181597/roth-mkm-initiates-mind-medicine-mnmdus-with-buy-rating-announces?futusource=news_stock_stockpagenews&ns_stock_id=37125992&report_id=37125992&report_type=stock&src=2&main_broker=WzEwMDdd&client_hour_clock=24&us_cid=73925127&channel=4&skintype=3&level=2&global_content={%22promote_content%22:%22mm:post:41181597%22,%22invite%22:73925127}&data_ticket=1721821266767476
$Mind Medicine (MNMD.US)$
$36 target!?!?
https://www.moomoo.com/news/post/41181597?futusource=news_stock_stockpagenews&ns_stock_id=37125992&report_id=37125992&report_type=stock&src=2&main_broker=WzEwMDdd&client_hour_clock=24&us_cid=73925127&channel=4&skintype=3&level=1&global_content=%7B%22promote_content%22%3A%22mm%3Apost%3A41181597%22%2C%22invite%22%3A73925127%7D&data_ticket=d852726825d53ffa91432d8eef415178
$36 target!?!?
https://www.moomoo.com/news/post/41181597?futusource=news_stock_stockpagenews&ns_stock_id=37125992&report_id=37125992&report_type=stock&src=2&main_broker=WzEwMDdd&client_hour_clock=24&us_cid=73925127&channel=4&skintype=3&level=1&global_content=%7B%22promote_content%22%3A%22mm%3Apost%3A41181597%22%2C%22invite%22%3A73925127%7D&data_ticket=d852726825d53ffa91432d8eef415178
1
2
$Mind Medicine (MNMD.US)$
A small position however, it isn't showing up on the ticker at all!
A small position however, it isn't showing up on the ticker at all!
3
$Mind Medicine (MNMD.US)$ Reuters· 3 mins ago
MindMed Announces Issuance of New Patent for Mm120 Orally Disintegrating Tablet (Odt)
MindMed Announces Issuance of New Patent for Mm120 Orally Disintegrating Tablet (Odt)
$Mind Medicine (MNMD.US)$
MindMed Announces Issuance of New Patent for MM120 Orally Disintegrating Tablet (ODT)
MindMed (NASDAQ: MNMD) has been granted a new patent by the USPTO for its MM120 (lysergide) orally disintegrating tablet (ODT) formulation. This patent, extending protection until 2041, covers the pharmaceutical formulation, manufacturing methods, and treatment applications for MM120 ODT. The formulation incorporates Catalent's Zydis® ODT technology, which MindMed believes will offe...
MindMed Announces Issuance of New Patent for MM120 Orally Disintegrating Tablet (ODT)
MindMed (NASDAQ: MNMD) has been granted a new patent by the USPTO for its MM120 (lysergide) orally disintegrating tablet (ODT) formulation. This patent, extending protection until 2041, covers the pharmaceutical formulation, manufacturing methods, and treatment applications for MM120 ODT. The formulation incorporates Catalent's Zydis® ODT technology, which MindMed believes will offe...
$Mind Medicine (MNMD.US)$ MindMed Reports Completion Of End-of-phase 2 Meeting With FDA; Says Reached Alignment On Phase 3 Development Strategy For MM120 In Generalized Anxiety Disorder
Benzinga· 2 mins ago
Rob Barrow, Chief Executive Officer of MindMed, said, "This marks a significant milestone for MindMed and for the millions of individuals affected by GAD. We are on schedule to initiate our Phase 3 clinical program for MM120 oral dissolving tablet (ODT) in GAD in the second half of this ...
Benzinga· 2 mins ago
Rob Barrow, Chief Executive Officer of MindMed, said, "This marks a significant milestone for MindMed and for the millions of individuals affected by GAD. We are on schedule to initiate our Phase 3 clinical program for MM120 oral dissolving tablet (ODT) in GAD in the second half of this ...
4
No comment yet
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data
convivial Penguin_29 OP : Mind Medicine Price Target Raised to $55.00/Share From $35.00 by HC Wainwright & Co.
convivial Penguin_29 OP : that's crazy people aren't piling in. I've been holding since before the reverse stock split. bought in before the reverse split at $2.00 and got cut down to damn near nothing for a price of 5.85 now. dafuque?
71679526 : Looks like we are working on the handle of the cup now. Tbd